ArticleNature communications2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Erratum issued Registry-linked trialAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07290088 (An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients), which is not on this map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07290088 phase2 / phase3recruitingnot on this mapstarted 2023, after this paper: background citation
An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients
Who cites it
38 citing papers in PubMed.
- The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.Cell reports. Medicine · 2025Trial
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- PTP4A3 dephosphorylates EGFR to promote metastasis and enhance sensitivity to lapatinib in hepatocellular carcinoma.Oncogene · 2026Article
- Etiology of polyploid giant cancer cells: a new frontier in cancer biology.Cancer cell international · 2026Review
- B cell receptor-based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens.Frontiers in immunology · 2026Article
- PRL-3 as a metastasis-associated phosphatase in colorectal cancer: Mechanisms and therapeutic strategies.Clinical & experimental metastasis · 2025Review
- Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs.Molecular oncology · 2025Article
- PRL-3: unveiling a new horizon in cancer therapy.Acta pharmacologica Sinica · 2025Review
- PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases.Nature communications · 2025Article
- Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release.The Journal of pharmacology and experimental therapeutics · 2025Article
- Melanocyte lineage dynamics in development, growth and disease.Development (Cambridge, England) · 2024Review
- Review
- Targeting PRL phosphatases in hematological malignancies.Expert opinion on therapeutic targets · 2024Review
- Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling.Biomolecules · 2024Review
- PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity.Theranostics · 2024Article
- Reprogramming Exosomes to Escape from Immune Surveillance for Mitochondrial Protection in Hepatic Ischemia-Reperfusion Injury.Theranostics · 2024Article
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.Molecular therapy oncolytics · 2023Article
- A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.Targeted oncology · 2023Article
- Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.Molecular cancer · 2023Article
- Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.Nature reviews. Drug discovery · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
29 authors.
Min Thura *Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Abdul Qader Al-Aidaroos *Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.ORCID http://orcid.org/0000-0003-0330-6606
Abhishek GuptaInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Cheng Ean CheeDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Soo Chin LeeDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Kam Man HuiDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Jie LiInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Yeoh Khay GuanDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore.
Wei Peng YongDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Jimmy SoDivision of Surgical Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Wee Joo ChngDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Chin Hin NgDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Jianbiao ZhouDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.ORCID http://orcid.org/0000-0002-5679-671X
Ling Zhi WangCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
John Shyi Peng YuenDepartment of Urology, Singapore General Hospital, Singapore, 169608, Singapore.
Henry Sun Sien HoDepartment of Urology, Singapore General Hospital, Singapore, 169608, Singapore.
Sim Mei YiDepartment of Urology, Singapore General Hospital, Singapore, 169608, Singapore.ORCID http://orcid.org/0000-0001-6546-4699
Edmund ChiongDivision of Surgical Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Su Pin ChooDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Joanne NgeowInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Matthew Chau Hsien NgDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Clarinda ChuaDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Eugene Shen Ann YeoDepartment of Colorectal Surgery, Singapore General Hospital, Singapore, 169608, Singapore.
Iain Bee Huat TanDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Joel Xuan En SngInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Nicholas Yan Zhi TanInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Jean Paul ThieryInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
Boon Cher GohDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
Qi ZengInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore. mcbzengq@imcb.a-star.edu.sg.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently expressed in several cancers. Here we show that PRL3-zumab specifically inhibits PRL3
Indexed as
AnimalsAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmAntineoplastic Agents, ImmunologicalB-LymphocytesCarcinoma, HepatocellularCell Line, TumorCytophagocytosisHepatocytesHep G2 CellsHumansImmunotherapyKiller Cells, NaturalLiver NeoplasmsAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntigens, NeoplasmAntineoplastic Agents, ImmunologicalNeoplasm ProteinsOncogene ProteinsProtein Tyrosine PhosphatasesPTP4A3 protein, humanReceptors, IgG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07290088ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.